A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Terminated · Phase 1 · NCT06158958
Conditions: Solid Tumors
At a glance
- Research payments reported, 2025
- $467,527
- U.S. investigators named
- 12
- Sites paid
- 18
- Planned or actual enrollment
- 27
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-303 (drug), Budigalimab (drug)
- Dates
- Started 2024-02-06; completion 2025-10-22
- Results posted
- Not yet
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy and in combination with budigalimab, (ABBV-181). ABBV-303 is an investigational drug being developed for the treatment of solid tumors. There are multiple treatment arms in this study. Participants will either receive ABBV-303 as a single agent or in combination with budigalimab (another investigational drug) at different doses. Approximately 181 adult participants will be enrolled in the study across sites worldwide. In Part A, ABBV-303 will be intravenously (IV) …
From ClinicalTrials.gov, last updated 2025-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $467,527 in research payments for this study in 2025 (153 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anthony B. El-khoueiry, M.D. Medical Oncology · Los Angeles, CA
- Jyoti Malhotra, M.D, MPH Hematology & Oncology · New Haven, CT
- Young Kwang Chae, MD, MPH, MBA Hematology & Oncology · Chicago, IL
- Shirish M. Gadgeel, MD Medical Oncology · Detroit, MI
- Manish Sharma, M.D. Medical Oncology · Grand Rapids, MI
- Anjali Rohatgi, MD Medical Oncology · Saint Louis, MO
- John D. Powderly II, M.D. Hematology & Oncology · Huntersville, NC
- Kristen R. Spencer, D.O. Medical Oncology · New Brunswick, NJ
- Dwight H. Owen, MD Medical Oncology · Columbus, OH
- Kyriakos P. Papadopoulos, M.D. Hematology & Oncology · San Antonio, TX
- David Sommerhalder Hematology & Oncology · San Antonio, TX
- Apostolia M. Tsimberidou, M.D., PHD Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $101,902
- New York University $67,978
- Carolina Biooncology Institute PLLC $61,962
- City of Hope National Medical Ctr $61,484
- Northwestern University $54,024
- Henry Ford Health Hospital, MI $39,830
- Washington University $17,900
- The Ohio State University $15,980
- South Texas Accelerated Research Therapeutics $11,739
- Start Midwest LLC $10,730
- Next Oncology $10,356
- University of Southern California $7,278
- Start San Antonio LLC $3,084
- Ohio State University $600
- NYU Langone Health $600
- Usc Norris Comprehensive Cancer Center $600
- Carolina Biooncology Institute $600
- $480
- Washington University in St Louis $400
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.